welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

(-)- Epicatechin Becker Muscular Dystrophy

key information

study id #: NCT03236662

condition: Becker Muscular Dystrophy

status: completed


This is a 48-week open-label extension of our initial proof-of-concept study (UCD0113) in patients with Becker muscular dystrophy who participated in the earlier trial. This single center study will enroll up to 10 adults who will receive the purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks. After screening visits, participants will be enrolled in the study if they meet all inclusion criteria. They will be evaluated at screening, baseline, and weeks 4, 8, 12, 24, 16 and 48. The main criterion for success of the study will be presence of one or more biologic or strength and performance outcome measures that yield a response magnitude that allows for sufficient power in a Phase II B study with a sample size of 30 individuals.

intervention: (-)-Epicatechin

mechanism of action: Antioxidant to support health

results: https://clinicaltrials.gov/ct2/show/results/NCT03236662

last updated: November 22, 2018